Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29

Kaixiong Tao,Ning Zhang,Guobin Wang,Xiangbai Wu
2006-01-01
World Chinese Journal of Digestology
Abstract:AIM: To investigate the effect of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), on the expression of vascular endothelial growth factor (VEGF) and angiopointin-2 (Ang-2) in colon carcinoma cell line HT-29. METHODS: The cultured HT-29 cells were treated with different concentrations of meloxicam (100, 200, 400, 800 μmol/L) for different time. The proliferation of HT-29 cells was detected by Cell Counting Kit 8 (CCK8). Cell cycle was detected by flow cytometry. The levels of VEGF and Ang-2 protein in the supernatants were determined by enzyme-linked immunosorbent assay (ELISA) and the expression of VEGF and Ang-2 mRNA in HT-29 cells were examined by real-time quantitative reverse-transcription-polymerase chain reaction (RT-PCR). RESULTS: Meloxicam inhibited the proliferation of HT-29 cells in a concentration- and time-dependent manner (P = 0.000→0.029; 0.000→ 0.043), and the proliferating activity was decreased with the increase of concentration and prolonging of action time. Meloxicam changed the cycles of HT-29 cells in a concentration-dependent manner, and the number of cells at G 0/G 1 phase was significantly increased (P = 0.000→ 0.015). The levels of VEGF and Ang-2 protein in supernatants were reduced gradually with the increase of concentration or action time (P = 0.000 →0.018; 0.000→0.028). The expression of COX-2, VEGF and Ang-2 mRNA were also reduced with the increase of Meloxicam concentration (P = 0.000→0.025). CONCLUSION: Meloxicam can reduce the expression of VEGF and Ang-2 at the levels of protein and mRNA in colon carcinoma cell line.
What problem does this paper attempt to address?